8 completed, 7 unknown, 1 not yet recruiting. 10 Phase 1, 4 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Unknown 3 |
| Phase 2 | 4 | Unknown 3, Completed 1 |
| Phase 3 | 4 | Unknown 3, Not yet recruiting 1 |
Follow Ahon Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy ET-26HCl 0.8mg/kg group, Etomidate Injectable Product 0.3mg/kg group - Gastroscopy, Colonoscopy | Phase 3 | Not yet recruiting | Ahon Pharmaceutical Co., Ltd. | 270 | 2025-03-01 | 2025-03-05 |
| A Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride in Gastroscopy/Colonoscopy ET-26HCl 0.6mg/kg group, ET-26HCl 0.8mg/kg group, Etomidate Injectable Product 0.3mg/kg group - Gastroscopy, Colonoscopy | Phase 2 | Completed | Ahon Pharmaceutical Co., Ltd. | 78 | 2024-11-15 | 2025-05-25 |
| Safety and Pharmacokinetics/ Pharmacodynamics of Methoxyethyl Etomidate Hydrochloride in Healthy Elderly Subjects ET-26HCl - Healthy Elderly Subjects | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 16 | 2023-12-25 | 2025-01-24 |
| Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride ET-26 - Hepatic Insufficiency | Phase 1 | Unknown | Ahon Pharmaceutical Co., Ltd. | 24 | 2023-12-06 | 2023-12-20 |
| Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride rifampicin, Fluconazole, Omeprazole - Interaction Drug Food | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 68 | 2023-12-04 | 2025-02-14 |
| Phase 1 Renal Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride ET-26HCl - Renal Insufficiency | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 24 | 2023-11-30 | 2024-12-27 |
| Clinical Trial of the Effect of Methoxyethyl Etomidate Hydrochloride on the QT Interval of the Heart ET-26 0.8mg/kg(low-dose) group, ET-26 2.8mg/kg(high dose) group - QT Interval, Variation in | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 18 | 2023-11-09 | 2025-02-14 |
| A Trial to Evaluate the Efficacy and Safety of Methoxyetomidate Hydrochloride for Injection (ET-26) for the Induction of General Anesthesia in Elective Surgery Subjects ET-26, Etomidate Injectable Emulsion - Anesthesia Induction | Phase 3 | Unknown | Ahon Pharmaceutical Co., Ltd. | 270 | 2023-10-11 | 2024-01-12 |
| Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency FCN-437c capsule - Hepatic Insufficiency | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 24 | 2023-09-04 | 2024-11-12 |
| Substance Balance Trial of Methoxyethyl Etomidate Hydrochloride Methoxyethyl Etomidate Hydrochloride - Pharmacokinetics | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 6 | 2023-07-17 | 2025-02-14 |
| Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects Low dose group, High dose group - Advanced Breast Cancer | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 18 | 2022-11-11 | 2024-03-04 |
| This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. FCN-437c, Letrozole or anastrozole, Goserelin acetate, Placebo, Letrozole or anastrozole, Goserelin acetate - Advanced Breast Cancer, Female Breast Cancer | Phase 3 | Unknown | Ahon Pharmaceutical Co., Ltd. | 434 | 2022-03-02 | 2022-07-06 |
| This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. FCN-437c,Fulvestrant,Goserelin acetate, Placebo,Fulvestrant,Goserelin acetate - Advanced Breast Cancer, Female Breast Cancer | Phase 3 | Unknown | Ahon Pharmaceutical Co., Ltd. | 312 | 2022-01-18 | 2022-07-05 |
| Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin FCN-437c+Fulvestrant, FCN-437c+Letrozole+Goserelin - Breast Neoplasms | Phase 2 | Unknown | Ahon Pharmaceutical Co., Ltd. | 70 | 2020-06-30 | 2021-08-13 |
| Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c FCN-437c, Letrozole 2.5mg - Breast Neoplasms | Phase 1 / Phase 2 | Unknown | Ahon Pharmaceutical Co., Ltd. | 78 | 2019-02-14 | 2020-07-27 |
| A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation FCN-411 Dose-escalation, FCN-411 Dose-expansion - Lung Cancer | Phase 1 / Phase 2 | Unknown | Ahon Pharmaceutical Co., Ltd. | 90 | 2018-08-01 | 2020-07-16 |
Breast Neoplasms (2) · Hepatic Insufficiency (2) · Lung Neoplasms (1) · Renal Insufficiency (1)
ET-26 compound (4) · FCN-437c (4) · Population Groups (4) · Goserelin (2) · Letrozole (2) · Anastrozole (1) · Fluconazole (1) · Midazolam (1) · Omeprazole (1) · Rifampin (1)
China (16)
Mengchang Yang (2) · Wei Zhao, Pharmaciae Doctor (2) · Binghe Xu (1) · Haiyan Li, MD (1) · Jin Liu (1) · Liyan Miao, Doctor (1) · Qing Wen, Master (1) · Wei Zhao, Doctor (1) · Xichun Hu (1) · Xichun Hu, M.D. (1) · Yanhua Ding, MD (1) · Yanhua Ding, PI (1) · Yuankai Shi, MD (1) · Yunjiang Liu, Doctor (1)
PMID 22452895, PMID 22452896, PMID 23816960, PMID 23816963, PMID 24439929, PMID 26156651, PMID 27577069, PMID 34109484, PMID 35248866, PMID 39188943, PMID 40663244, PMID 42224659, PMID 42597983